{"id":445617,"date":"2026-06-16T05:58:00","date_gmt":"2026-06-15T21:58:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=445617"},"modified":"2026-06-16T05:58:00","modified_gmt":"2026-06-15T21:58:00","slug":"%e7%be%8e%e7%b4%8d%e9%87%8c%e5%b0%bc%e9%9b%86%e5%9c%98%e6%96%bc-2026-%e5%b9%b4%e6%ad%90%e6%b4%b2%e8%a1%80%e6%b6%b2%e5%ad%b8%e5%8d%94%e6%9c%83-eha-%e5%b9%b4%e6%9c%83%e5%85%ac%e4%bd%88-selinexor","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=445617","title":{"rendered":"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002<\/i><\/li>\n<li><i>\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002<\/i><\/li>\n<li><i>\u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002<\/i><\/li>\n<li><i>\u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002<\/i><\/li>\n<\/ul>\n<p class=\"prntac\"><b>\u50c5<\/b><b>\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1<\/b><\/p>\n<p><span class=\"legendSpanClass\">\u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d04<\/span><span class=\"legendSpanClass\">2026\u5e746\u670816\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5<a href=\"https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4214969\/claire.harrison.selinexor.plus.ruxolitinib.in.janus.kinse.inhibitornave.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2934%2Amarker%3D6763\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a<\/a>[i]\u5f62\u5f0f\u767c\u8868\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">  <\/div>\n<p>SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002.<\/p>\n<p>\u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Selinexor \u806f\u5408 Ruxolitinib (n=235)<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>\u5b89\u6170\u5291 + Ruxolitinib (n=118)<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>\u7b2c 12 \u9031\u6642\u7684 SVR35<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">49.4% (n=116)<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">20.3% (n=24)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>\u7b2c 24 \u9031\u6642\u7684 SVR35<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">49.8% (n=117)<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">28.0% (n=33)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>\u7b2c 36 \u9031\u6642\u7684 SVR35*<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">46.9% (n=97)<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">23.0% (n=23)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">* \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>Guy&#8217;s and St. Thomas&#8217; NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d<\/p>\n<p><b>\u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a<\/b>\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002<\/li>\n<li><b>\u7e3d\u5b58\u6d3b\u671f (OS)\uff1a<\/b>\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002<\/li>\n<li><b>\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a<\/b>\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002<\/li>\n<li><b>\u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e<\/b>\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002<\/li>\n<li><b>\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027<\/b>\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002<\/li>\n<\/ul>\n<p>\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d<\/p>\n<p><b>\u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF)<\/b><\/p>\n<p>\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002<sup> 1,2,3<\/sup><\/p>\n<p>\u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1a<a href=\"mailto:adverseevents@menarinistemline.com\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">adverseevents@menarinistemline.com<\/a>\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc <a href=\"https:\/\/stemline.com\/contact\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/stemline.com\/contact\/<\/a> \u67e5\u95b1\u3002<\/p>\n<p>\u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0<a href=\"https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1537.htm\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.ec.europa.eu<\/a> \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002<\/p>\n<p>\u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc<a href=\"https:\/\/www.karyopharm.com\/wp-content\/uploads\/2019\/07\/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">\u6b64\u8655<\/a>\u67e5\u95b1\u3002<\/p>\n<p><b>\u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718<\/b><\/p>\n<p>\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.menarini.com&amp;esheet=53558844&amp;newsitemid=20230920907427&amp;lan=en-US&amp;anchor=www.menarini.com&amp;index=5&amp;md5=7682feaaefe280a649c9a9d8a9e54a2c\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.menarini.com<\/a>\u3002<\/p>\n<p><b>\u95dc\u65bc Stemline Therapeutics, Inc.<\/b><br \/>Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 <i>ESR1<\/i> \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002<\/p>\n<p><b>\u53c3\u8003\u8cc7\u6599<\/b><\/p>\n<p>1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). <a href=\"https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/<\/a><br \/>2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). <a href=\"https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf<\/a><br \/>3.\u00a0 Myelofibrosis. Mayo Clinic. <a href=\"https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057<\/a><\/p>\n<p><sup>[i] <\/sup>\u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Selinexor \u806f\u5408 Ru&#8230;<\/p>\n","protected":false},"author":16,"featured_media":445618,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-445617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002  \u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002  \u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002  \u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e746\u670816\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a\u5f62\u5f0f\u767c\u8868\u3002   SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002. \u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002             Selinexor \u806f\u5408 Ruxolitinib (n=235)   \u5b89\u6170\u5291 + Ruxolitinib (n=118)        \u7b2c 12 \u9031\u6642\u7684 SVR35   49.4% (n=116)   20.3% (n=24)        \u7b2c 24 \u9031\u6642\u7684 SVR35   49.8% (n=117)   28.0% (n=33)        \u7b2c 36 \u9031\u6642\u7684 SVR35*   46.9% (n=97)   23.0% (n=23)        * \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005        Guy&#039;s and St. Thomas&#039; NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d \u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a   \u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002  \u7e3d\u5b58\u6d3b\u671f (OS)\uff1a\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002  \u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002  \u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002  \u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002  \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d \u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002 1,2,3 \u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1aadverseevents@menarinistemline.com\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc https:\/\/stemline.com\/contact\/ \u67e5\u95b1\u3002 \u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0www.ec.europa.eu \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002 \u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc\u6b64\u8655\u67e5\u95b1\u3002 \u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u53c3\u8003\u8cc7\u6599 1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf3.\u00a0 Myelofibrosis. Mayo Clinic. https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057  \u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=445617\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002  \u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002  \u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002  \u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e746\u670816\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a\u5f62\u5f0f\u767c\u8868\u3002   SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002. \u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002             Selinexor \u806f\u5408 Ruxolitinib (n=235)   \u5b89\u6170\u5291 + Ruxolitinib (n=118)        \u7b2c 12 \u9031\u6642\u7684 SVR35   49.4% (n=116)   20.3% (n=24)        \u7b2c 24 \u9031\u6642\u7684 SVR35   49.8% (n=117)   28.0% (n=33)        \u7b2c 36 \u9031\u6642\u7684 SVR35*   46.9% (n=97)   23.0% (n=23)        * \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005        Guy&#039;s and St. Thomas&#039; NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d \u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a   \u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002  \u7e3d\u5b58\u6d3b\u671f (OS)\uff1a\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002  \u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002  \u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002  \u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002  \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d \u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002 1,2,3 \u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1aadverseevents@menarinistemline.com\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc https:\/\/stemline.com\/contact\/ \u67e5\u95b1\u3002 \u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0www.ec.europa.eu \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002 \u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc\u6b64\u8655\u67e5\u95b1\u3002 \u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u53c3\u8003\u8cc7\u6599 1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf3.\u00a0 Myelofibrosis. Mayo Clinic. https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057  \u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=445617\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T21:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1990\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da\",\"datePublished\":\"2026-06-15T21:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617\"},\"wordCount\":192,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617\",\"name\":\"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"datePublished\":\"2026-06-15T21:58:00+00:00\",\"description\":\"Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002 \u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002 \u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002 \u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002 \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e746\u670816\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a\u5f62\u5f0f\u767c\u8868\u3002 SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002. \u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002 Selinexor \u806f\u5408 Ruxolitinib (n=235) \u5b89\u6170\u5291 + Ruxolitinib (n=118) \u7b2c 12 \u9031\u6642\u7684 SVR35 49.4% (n=116) 20.3% (n=24) \u7b2c 24 \u9031\u6642\u7684 SVR35 49.8% (n=117) 28.0% (n=33) \u7b2c 36 \u9031\u6642\u7684 SVR35* 46.9% (n=97) 23.0% (n=23) * \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005 Guy's and St. Thomas' NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d \u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a \u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002 \u7e3d\u5b58\u6d3b\u671f (OS)\uff1a\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002 \u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002 \u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002 \u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d \u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002 1,2,3 \u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1aadverseevents@menarinistemline.com\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc https:\\\/\\\/stemline.com\\\/contact\\\/ \u67e5\u95b1\u3002 \u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0www.ec.europa.eu \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002 \u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc\u6b64\u8655\u67e5\u95b1\u3002 \u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u53c3\u8003\u8cc7\u6599 1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). https:\\\/\\\/rarediseases.org\\\/mondo-disease\\\/myelofibrosis\\\/2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). https:\\\/\\\/bloodcancerunited.org\\\/blood-cancer\\\/myeloproliferative-neoplasms-mpns\\\/myelofibrosis-mf3.\u00a0 Myelofibrosis. Mayo Clinic. https:\\\/\\\/www.mayoclinic.org\\\/diseases-conditions\\\/myelofibrosis\\\/symptoms-causes\\\/syc-20355057 \u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"width\":400,\"height\":121},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445617#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002  \u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002  \u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002  \u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e746\u670816\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a\u5f62\u5f0f\u767c\u8868\u3002   SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002. \u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002             Selinexor \u806f\u5408 Ruxolitinib (n=235)   \u5b89\u6170\u5291 + Ruxolitinib (n=118)        \u7b2c 12 \u9031\u6642\u7684 SVR35   49.4% (n=116)   20.3% (n=24)        \u7b2c 24 \u9031\u6642\u7684 SVR35   49.8% (n=117)   28.0% (n=33)        \u7b2c 36 \u9031\u6642\u7684 SVR35*   46.9% (n=97)   23.0% (n=23)        * \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005        Guy's and St. Thomas' NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d \u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a   \u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002  \u7e3d\u5b58\u6d3b\u671f (OS)\uff1a\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002  \u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002  \u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002  \u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002  \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d \u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002 1,2,3 \u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1aadverseevents@menarinistemline.com\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc https:\/\/stemline.com\/contact\/ \u67e5\u95b1\u3002 \u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0www.ec.europa.eu \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002 \u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc\u6b64\u8655\u67e5\u95b1\u3002 \u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u53c3\u8003\u8cc7\u6599 1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf3.\u00a0 Myelofibrosis. Mayo Clinic. https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057  \u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=445617","og_locale":"zh_TW","og_type":"article","og_title":"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002  \u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002  \u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002  \u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e746\u670816\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a\u5f62\u5f0f\u767c\u8868\u3002   SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002. \u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002             Selinexor \u806f\u5408 Ruxolitinib (n=235)   \u5b89\u6170\u5291 + Ruxolitinib (n=118)        \u7b2c 12 \u9031\u6642\u7684 SVR35   49.4% (n=116)   20.3% (n=24)        \u7b2c 24 \u9031\u6642\u7684 SVR35   49.8% (n=117)   28.0% (n=33)        \u7b2c 36 \u9031\u6642\u7684 SVR35*   46.9% (n=97)   23.0% (n=23)        * \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005        Guy's and St. Thomas' NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d \u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a   \u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002  \u7e3d\u5b58\u6d3b\u671f (OS)\uff1a\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002  \u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002  \u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002  \u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002  \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d \u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002 1,2,3 \u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1aadverseevents@menarinistemline.com\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc https:\/\/stemline.com\/contact\/ \u67e5\u95b1\u3002 \u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0www.ec.europa.eu \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002 \u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc\u6b64\u8655\u67e5\u95b1\u3002 \u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u53c3\u8003\u8cc7\u6599 1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf3.\u00a0 Myelofibrosis. Mayo Clinic. https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057  \u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=445617","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2026-06-15T21:58:00+00:00","og_image":[{"width":3000,"height":1990,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445617"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da","datePublished":"2026-06-15T21:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445617"},"wordCount":192,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=445617","url":"https:\/\/pingtungtimes.com.tw\/?p=445617","name":"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","datePublished":"2026-06-15T21:58:00+00:00","description":"Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u9054 49.8%\uff0c\u5c0d\u7167\u7d44\u5247\u70ba 28%\uff0c\u986f\u793a\u5177\u7d71\u8a08\u5b78\u986f\u8457\u6539\u5584\u3002 \u7b2c 3 \u671f SENTRY \u8a66\u9a57\u7684\u4e8b\u5f8c\u5206\u6790 (post-hoc analysis) \u986f\u793a\uff0cSVR35 \u53ef\u80fd\u9810\u6e2c\u7e3d\u5b58\u6d3b\u671f (OS)\uff1b\u800c\u7b2c 1 \u671f SENTRY \u8a66\u9a57\u7684\u65b0\u6578\u64da\u4ea6\u986f\u793a\u51fa\u985e\u4f3c\u7d50\u679c\u3002 \u6709\u95dc\u6578\u64da\u7372 EHA \u79d1\u5b78\u9805\u76ee\u59d4\u54e1\u6703\u9078\u70ba\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a (late-breaking oral presentation)\u3002 \u6709\u95dc\u6578\u64da\u6e90\u81ea\u8207 Karyopharm Therapeutics, Inc. \u5408\u4f5c\u9032\u884c\u7684\u95dc\u9375\u6027\u7814\u7a76\u3002 \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u754c\u5a92\u9ad4\u53c3\u95b1 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e746\u670816\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff08\u300cMenarini\u300d\uff09\u4ee5\u53ca\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u816b\u7624\u6cbb\u7642\u65b9\u6848\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u8207\u95dc\u9375\u6027\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u76f8\u95dc\u7684\u65b0\u6578\u64da\u5c07\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u4e0a\u4ee5\u6700\u65b0\u7a81\u7834\u6027\u7814\u7a76\u53e3\u982d\u5831\u544a\u5f62\u5f0f\u767c\u8868\u3002 SENTRY (NCT04562389) \u662f\u4e00\u9805\u95dc\u9375\u6027\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u63a1\u7528\u96a8\u6a5f\u5206\u914d\u3001\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\uff0c\u6bd4\u8f03 60 \u6beb\u514b Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u4e00\u7dda\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u60a3\u8005 (n=353)\uff0c\u8207 Ruxolitinib\u55ae\u85e5\u6cbb\u7642\u7684\u7642\u6548\u3002 SENTRY \u8a66\u9a57\u7531 Karyopharm Therapeutics, Inc. \u8207\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5408\u4f5c\u9032\u884c\uff0c\u65e8\u5728\u8a55\u4f30\u5169\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff1a\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f 35% \u6216\u4ee5\u4e0a (SVR35)\uff0c\u4ee5\u53ca\u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\u3002. \u8a72\u8a66\u9a57\u9054\u5230\u9996\u500b\u5171\u540c\u4e3b\u8981\u7d42\u9ede\uff0c\u7d50\u679c\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408 Ruxolitinib\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u7387 (SVR35) \u8f03\u55ae\u7368\u63a5\u53d7Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u6709\u660e\u986f\u4e14\u5177\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u6539\u5584\u3002 \u6709\u95dc\u7d50\u679c\u986f\u793a\uff0c\u806f\u5408\u6cbb\u7642\u7d44\u53ef\u5be6\u73fe\u5feb\u901f\u3001\u986f\u8457\u4e14\u6301\u7e8c\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u3002 Selinexor \u806f\u5408 Ruxolitinib (n=235) \u5b89\u6170\u5291 + Ruxolitinib (n=118) \u7b2c 12 \u9031\u6642\u7684 SVR35 49.4% (n=116) 20.3% (n=24) \u7b2c 24 \u9031\u6642\u7684 SVR35 49.8% (n=117) 28.0% (n=33) \u7b2c 36 \u9031\u6642\u7684 SVR35* 46.9% (n=97) 23.0% (n=23) * \u5206\u6790\u6db5\u84cb\u5df2\u5b8c\u6210\u813e\u81df\u8a55\u4f30\u6216\u65bc\u7b2c 36 \u9031\u524d\u9000\u51fa\u7814\u7a76\u7684\u60a3\u8005 Guy's and St. Thomas' NHS Foundation Trust \u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624\u5b78\u6559\u6388\u517c\u526f\u9996\u5e2d\u91ab\u7642\u7e3d\u76e3 Claire Harrison \u535a\u58eb\u8868\u793a\uff1a\u300c\u5be6\u73fe\u813e\u81df\u7e2e\u5c0f\u662f\u9aa8\u9ad3\u7e96\u7dad\u5316\u6cbb\u7642\u7684\u6838\u5fc3\u76ee\u6a19\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cSENTRY \u8a66\u9a57\u6240\u986f\u793a\u7684\u813e\u81df\u7e2e\u5c0f\u6548\u679c\u4e0d\u4f46\u8d77\u6548\u8fc5\u901f\uff0c\u800c\u4e14\u5e45\u5ea6\u986f\u8457\u4e14\u6301\u4e45\uff0c\u4e26\u8207\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u60a3\u8005\u7684\u6f5b\u5728\u7e3d\u5b58\u6d3b\u671f\u7372\u76ca\u76f8\u95dc\uff0c \u6211\u5011\u5c0d\u9019\u4e9b\u7d50\u679c\u611f\u5230\u9f13\u821e\uff0c\u56e0\u70ba\u9019\u4ee3\u8868\u6709\u671b\u70ba\u8feb\u5207\u9700\u8981\u66f4\u4f73\u6cbb\u7642\u9078\u64c7\u7684\u60a3\u8005\u5e36\u4f86\u65b0\u7684\u6cbb\u7642\u9032\u5c55\u3002\u300d \u5176\u4ed6\u91cd\u9ede\u7d50\u679c\u5305\u62ec\uff1a \u7e3d\u75c7\u72c0\u8a55\u5206\u7d55\u5c0d\u503c (Abs-TSS)\uff1a\u806f\u5408\u6cbb\u7642\u7d44\u6240\u5c55\u73fe\u7684\u6548\u76ca\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u82e5\u3002\u65bc\u7b2c 24 \u9031\u6642\uff0c\u63a5\u53d7\u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005 Abs-TSS \u6539\u5584 9.9 \u5206\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u6539\u5584 10.9 \u5206\u3002 \u5169\u7d44\u4e4b\u9593\u7684\u5dee\u7570\u672a\u9054\u7d71\u8a08\u5b78\u986f\u8457\u6c34\u5e73\uff0c\u56e0\u6b64\u806f\u5408\u6cbb\u7642\u7d44\u672a\u80fd\u9054\u5230\u7b2c\u4e8c\u9805\u5171\u540c\u4e3b\u8981\u7d42\u9ede\u3002 \u7e3d\u5b58\u6d3b\u671f (OS)\uff1a\u5118\u7ba1\u65bc\u5206\u6790\u6642\u76f8\u95dc\u6578\u64da\u5c1a\u672a\u6210\u719f\uff0c\u4f46\u8207\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u76f8\u6bd4\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5df2\u986f\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f (OS) \u8a0a\u865f\u3002OS \u70ba\u9810\u5148\u6307\u5b9a\u7684\u6b21\u8981\u7d42\u9ede\u4e4b\u4e00\u3002 \u7814\u7a76\u986f\u793a\uff0c\u63a5\u53d7 Selinexor \u806f\u5408\u6cbb\u7642\u7684\u60a3\u8005\u6b7b\u4ea1\u98a8\u96aa\u964d\u4f4e\u8d85\u904e 50% (HR 0.43)\u3002 \u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\uff1a\u5728\u5404\u500b\u9810\u5148\u6307\u5b9a\u7684\u4e9e\u7d44\u5206\u6790\u4e2d\uff0c\u5747\u89c0\u5bdf\u5230\u4e00\u81f4\u7684 SVR35 \u7372\u76ca\u3002 \u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0c\u4e0d\u8ad6 Ruxolitinib \u7684\u5291\u91cf\u9ad8\u4f4e\uff0c\u5305\u62ec\u6bcf\u65e5\u63a5\u53d7\u5c11\u65bc 15 \u6beb\u514b Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\uff0cSelinexor \u806f\u5408\u6cbb\u7642\u5747\u80fd\u5be6\u73fe\u66f4\u512a\u8d8a\u7684\u813e\u81df\u9ad4\u7a4d\u7e2e\u5c0f\u6548\u679c\u3002 \u8b8a\u7570\u7b49\u4f4d\u57fa\u56e0\u983b\u7387 (VAF) \u964d\u4f4e\uff1a\u9019\u9805\u8207 SVR35 \u76f8\u95dc\u7684\u9810\u5148\u6307\u5b9a\u63a2\u7d22\u6027\u7d42\u9ede\u986f\u793a\uff0c\u65bc\u7b2c 24 \u9031\u6642\uff0cSelinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u7d44\u6709 32% \u7684\u60a3\u8005\u9304\u5f97 VAF \u4e0b\u964d\uff0c\u800c\u55ae\u7368\u63a5\u53d7 Ruxolitinib \u6cbb\u7642\u7684\u60a3\u8005\u5247\u70ba 23.9%\uff0c\u986f\u793a\u8a72\u806f\u5408\u6cbb\u7642\u5177\u5099\u6f5b\u5728\u7684\u75be\u75c5\u4fee\u98fe\u4f5c\u7528\u3002 \u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\uff1a\u8a72\u806f\u5408\u6cbb\u7642\u5c55\u73fe\u51fa\u53ef\u7ba1\u7406\u7684\u5b89\u5168\u6027\u53ca\u8010\u53d7\u6027\u7279\u5fb5\uff0c\u8207 Selinexor \u53ca Ruxolitinib \u5404\u81ea\u5df2\u77e5\u7684\u5b89\u5168\u6027\u6982\u6cc1\u4e00\u81f4\u3002 \u7814\u7a76\u4e2d\u672a\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u65b0\u7684\u5b89\u5168\u6027\u8a0a\u865f\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300cSENTRY \u7814\u7a76\u6240\u986f\u793a\u7684\u5f37\u52c1\u813e\u81df\u53cd\u61c9\uff0c\u4ee5\u53ca\u4ee4\u4eba\u9f13\u821e\u7684\u65e9\u671f\u7e3d\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u70ba\u53d7\u9019\u7a2e\u56b4\u91cd\u75be\u75c5\u56f0\u64fe\u4e14\u9810\u5f8c\u6b20\u4f73\u7684\u60a3\u8005\u5e36\u4f86\u4e86\u6f5b\u5728\u65b0\u6cbb\u7642\u65b9\u6848\u7684\u5e0c\u671b\u3002 \u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u9019\u4efd\u6c7a\u5fc3\u8207\u627f\u8afe\u6bd4\u4ee5\u5f80\u4efb\u4f55\u6642\u5019\u90fd\u66f4\u5805\u5b9a\u3002\u300d \u95dc\u65bc\u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u9aa8\u9ad3\u7e96\u7dad\u5316 (MF) \u662f\u4e00\u7a2e\u8840\u764c\uff0c\u5c6c\u65bc\u4e00\u7d44\u7a31\u70ba\u9aa8\u9ad3\u589e\u6b96\u6027\u816b\u7624 (Myeloproliferative Neoplasms\uff0cMPN) \u7684\u75be\u75c5\u3002 \u9019\u985e\u75be\u75c5\u7531\u9aa8\u9ad3\u5167\u7570\u5e38\u9020\u8840\u7d30\u80de\u904e\u5ea6\u589e\u751f\u6240\u5f15\u8d77\uff0c\u4e26\u5c0e\u81f4\u7622\u75d5\u7d44\u7e54\u5f62\u6210\u3002 \u6709\u95dc\u7622\u75d5\u7d44\u7e54\u6703\u59a8\u7919\u8eab\u9ad4\u88fd\u9020\u5065\u5eb7\u8840\u7d30\u80de\u3002 \u9aa8\u9ad3\u7e96\u7dad\u5316\u5c6c\u7f55\u898b\u75be\u75c5\uff0c\u6bcf 10 \u842c\u4eba\u7576\u4e2d\u6bcf\u5e74\u50c5\u7d04\u6709\u4e00\u81f3\u5169\u4eba\u78ba\u8a3a\uff0c\u800c\u60a3\u8005\u78ba\u8a3a\u5f8c\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba\u516d\u5e74\u3002 \u6b64\u5916\uff0c\u9aa8\u9ad3\u7e96\u7dad\u5316\u60a3\u8005\u7684\u751f\u6d3b\u8cea\u7d20\u4ea6\u53ef\u80fd\u56e0\u75be\u75c5\u5f15\u8d77\u7684\u75c7\u72c0\u800c\u53d7\u5230\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u813e\u81df\u816b\u5927\u53ca\u8840\u7403\u6578\u76ee\u504f\u4f4e\u7b49\u3002 1,2,3 \u5982\u9700\u901a\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff1aadverseevents@menarinistemline.com\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u6599\u5747\u53ef\u65bc https:\/\/stemline.com\/contact\/ \u67e5\u95b1\u3002 \u8acb\u53c3\u95b1\u7522\u54c1\u7279\u6027\u6458\u8981 (SmPC) \u53ca\u8f09\u65bc\u00a0www.ec.europa.eu \u7684\u6b50\u6d32\u516c\u5171\u8a55\u4f30\u5831\u544a (European Public Assessment Report)\u3002 \u5982\u6b32\u4e86\u89e3 Selinexor \u7372\u6279\u51c6\u9069\u61c9\u75c7\u7684\u5b8c\u6574\u8cc7\u6599\uff0c\u8acb\u53c3\u95b1\u7576\u5730\u8655\u65b9\u8cc7\u8a0a\u3002\u00a0\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u6301\u6709 Selinexor \u7684\u6388\u6b0a\u8a31\u53ef\u6b0a\uff0c\u73fe\u6642\u5df2\u65bc\u591a\u500b\u6b50\u6d32\u570b\u5bb6\u53ca\u5168\u7403\u591a\u500b\u5730\u5340\u63a8\u51fa\u8a72\u85e5\u7269\u3002 \u5728\u7f8e\u570b\uff0cSelinexor \u7531 Karyopharm Therapeutics \u8ca0\u8cac\u92b7\u552e\uff0c\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u65bc\u6b64\u8655\u67e5\u95b1\u3002 \u95dc\u65bc\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u662f\u4e00\u5bb6\u9818\u5148\u7684\u570b\u969b\u88fd\u85e5\u53ca\u8a3a\u65b7\u4f01\u696d\uff0c\u71df\u696d\u984d\u9054 55 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u4eba\u6578\u8d85\u904e 17,000 \u4eba\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u5c08\u6ce8\u65bc\u91ab\u7642\u9700\u6c42\u9ad8\u5ea6\u672a\u88ab\u6eff\u8db3\u7684\u6cbb\u7642\u9818\u57df\uff0c\u696d\u52d9\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u547c\u5438\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u6cbb\u7642\u7b49\u9818\u57df\u3002 \u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u5728\u5168\u7403\u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u5176\u7522\u54c1\u65bc\u5168\u7403 140 \u500b\u570b\u5bb6\u548c\u5730\u5340\u92b7\u552e\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics, Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u5546\u696d\u5316\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u65bc\u70ba\u60a3\u8005\u5e36\u4f86\u5177\u8b8a\u9769\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u6cbb\u7642\u85e5\u7269\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u7d55\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\uff0c\u5176\u816b\u7624\u5c6c\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 2 (HER2) \u9670\u6027\uff0c\u4ee5\u53ca\u5e36\u6709 ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e14\u75c5\u60c5\u5df2\u5728\u63a5\u53d7\u81f3\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u51fa\u73fe\u9032\u5c55\u3002 Stemline \u4ea6\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e Tagraxofusp-erzs\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\u3002BPDCN \u662f\u4e00\u7a2e\u4fb5\u8972\u6027\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u6b64\u5916\uff0cStemline \u4ea6\u65bc\u6b50\u6d32\u92b7\u552e Selinexor\u3002Selinexor \u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 \u6291\u5236\u5291\u3002 \u516c\u53f8\u76ee\u524d\u4ea6\u6b63\u5206\u5225\u5c31 Elacestrant \u53ca Tagraxofusp \u9032\u884c\u591a\u9805\u64f4\u5c55\u9069\u61c9\u75c7\u7814\u7a76\uff0c\u6db5\u84cb\u4e73\u764c\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7b49\u7bc4\u7587\uff1b\u540c\u6642\uff0c\u516c\u53f8\u4ea6\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u591a\u6b3e\u5019\u9078\u85e5\u7269\u6b63\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\uff0c\u6db5\u84cb\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u53ca\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u3002 \u53c3\u8003\u8cc7\u6599 1.\u00a0 Myelofibrosis. NORD (National Organization for Rare Disorders). https:\/\/rarediseases.org\/mondo-disease\/myelofibrosis\/2.\u00a0 Myelofibrosis. The Leukemia &amp; Lymphoma Society (LLS). https:\/\/bloodcancerunited.org\/blood-cancer\/myeloproliferative-neoplasms-mpns\/myelofibrosis-mf3.\u00a0 Myelofibrosis. Mayo Clinic. https:\/\/www.mayoclinic.org\/diseases-conditions\/myelofibrosis\/symptoms-causes\/syc-20355057 \u672c\u65b0\u805e\u7a3f\u6240\u8a0e\u8ad6\u7684\u7814\u7a76\u6027\u806f\u5408\u6cbb\u7642\u53ca\u672a\u7372\u6279\u51c6\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u6027\u53ca\u7642\u6548\u5c1a\u672a\u7372\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u78ba\u8a8d\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=445617"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","width":400,"height":121},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=445617#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\u65bc 2026 \u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703 (EHA) \u5e74\u6703\u516c\u4f48 Selinexor \u806f\u5408 Ruxolitinib \u6cbb\u7642\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u7b2c 3 \u671f SENTRY \u8a66\u9a57\u6578\u64da"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/445617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=445617"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/445617\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/445618"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=445617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=445617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=445617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}